Pei-Mei Chai

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma

Kueian Chen, W. Jeng, Chen-Chun Lin, 2022, Cancer medicine.

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma

Chao-Wei Lee, C. Hung, K. Pan, 2022, Biomedicines.

Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.

J. Hsieh, Chen-Chun Lin, W. Teng, 2022, American journal of cancer research.

Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization

I. Sheen, K. Lui, W. Jeng, 2022, Diagnostics.

Significance of Physical Status and Liver Function Reserve for Outcome of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib Treatment

Wei-Chen Lee, Hsin-Yi Lien, Yu-Chao Wang, 2023, Journal of hepatocellular carcinoma.

Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma

D. Tsan, Eric Yi-Liang Shen, Po-Ting Lin, 2024, The oncologist.